Bluepen Laboratories Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 13-12-2024
- Paid Up Capital ₹ 0.10 M
as on 13-12-2024
- Company Age 6 Year, 1 Month
- Last Filing with ROC 31 Mar 2022
- Revenue 119.27%
(FY 2022)
- Profit 83.82%
(FY 2022)
- Ebitda 1539.06%
(FY 2022)
- Net Worth 41.52%
(FY 2022)
- Total Assets -5.28%
(FY 2022)
About Bluepen Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Manoj Kumar and Anupama Sahoo serve as directors at the Company.
- CIN/LLPIN
U74994UR2018PTC009272
- Company No.
009272
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Dec 2018
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Dehradun, Uttarakhand, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Bluepen Laboratories Private Limited offer?
Bluepen Laboratories Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Common Disease Medicines, Antihistamines, Antibiotic Tablets & Capsules, Cefixime Tablet, Antibacterial Drugs, Cefpodoxime Dry Syrup, Antiseptic Gel, Lotion & Cream, Povidone Iodine Ointment.
Who are the key members and board of directors at Bluepen Laboratories?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Kumar  | Director | 03-Dec-2018 | Current |
| Anupama Sahoo | Director | 03-Dec-2018 | Current |
Financial Performance of Bluepen Laboratories.
Bluepen Laboratories Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 119.27% increase. The company also saw a substantial improvement in profitability, with a 83.82% increase in profit. The company's net worth Soared by an impressive increase of 41.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bluepen Laboratories?
In 2022, Bluepen Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bluepen Laboratories?
Unlock and access historical data on people associated with Bluepen Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bluepen Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bluepen Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
